HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

SAN DIEGO - Two different novel targeted therapies can produce strong responses in patients who have become resistant to Gleevec(tm), the standard therapy for chronic myeloid leukemia (CML), researchers at The University of Texas M. D. Anderson Cancer Center are reporting.

Researchers say the benefits offered by these drugs, BMS-354825 and AMN107, appear to be promising for treatment of relapsed CML and offer an immediate effective option for the minority of patients who do not achieve an optimal response to Gleevec therapy.

M. D. Anderson Cancer Center, the only institution to have tested both of these novel compounds, undertook independent Phase I clinical trials of both agents. It conducted the study of BMS-354825 in conjunction with the University of California, Los Angeles, and the study of AMN107 with the University of Frankfurt, in Germany. The M. D. Anderson researchers will discuss their experiences using these agents in patients with leukemia at the American Society of Hematology (ASH) meeting.

BMS-354825 "shows remarkable activity"

In the study conducted at M. D. Anderson and at UCLA School of Medicine, the majority of patients with advanced, Gleevec-resistant CML have responded to the drug BMS-354825, says Moshe Talpaz, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson.

Of 11 patients with advanced "blast phase" CML, seven have had a hematologic response from the drug (defined as control of white blood cell counts). Of these, three patients experienced a complete hematologic response (disappearance of all findings consistent with advanced stage CML, and return of blood counts to normal), while two patients showed no evidence of leukemia. Two other patients had their CML downgraded to "chronic." Additionally, of the 11 patients, four have had a major "cytogenetic response" (defined as elimination of cells with the cancer-causing defect), and two had minor cytogenetic response
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/10/2020)... ... January 10, 2020 , ... Ziegler, ... financial advisor to Radiology Ltd. on its partnership with US Radiology Specialists (“USRS”), ... in 1933, Radiology Ltd. is the largest private practice radiology group and outpatient ...
(Date:1/10/2020)... ... 10, 2020 , ... As multidisciplinary specialists from rheumatologists to ... event and education company, today announced the launch of the Autoimmune Learning Network, ... serves as a robust digital hub of information and education focused on care ...
(Date:1/10/2020)... ... January 10, 2020 , ... ... announced that it will be attending the HIMSS (Healthcare Information and Management Systems ... HIMSS is the can’t-miss health information and technology event of the year, where ...
(Date:1/10/2020)... (PRWEB) , ... January 10, 2020 , ... ... today announced that its Certified Pediatric Emergency Nurse (CPEN) specialty nursing ... (ABSNC). , The CPEN is a national board certification earned by registered ...
(Date:1/8/2020)... ... January 08, 2020 , ... Myant Inc., leaders in Textile ... powered by the Myant Platform at CES 2020, happening January 7-10, in ... to the Myant Platform will be aware of the worker’s current physical and ...
Breaking Medicine News(10 mins):
(Date:1/3/2020)... ... January 03, 2020 , ... ... radiologists to identify potential breast cancers earlier and faster, say a new international ... already using the Transpara system in 15 countries, including Hungary, Turkey, the USA ...
(Date:1/3/2020)... TORONTO (PRWEB) , ... January 03, 2020 , ... Stay ... pharma, biotech, medical device and food industries. Access to all webinars is free, so ... stay relevant in your field. , Visit http://www.xtalks.com to see our upcoming ...
(Date:1/3/2020)... ... January 03, 2020 , ... Complia Health announced today ... business will offer enterprise solutions for home, residential and community care in Canada, ... contracts and will move forward under the AlayaCare brand. , Procura has delivered ...
Breaking Medicine Technology:
Cached News: